Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy

被引：17

作者：

Abcouwer, Steven F. ^{[1
]}

机构：

[1] Univ Michigan, Coll Med, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA

来源：

DIABETES | 2013年 / 62卷 / 01期

关键词：

PROTEIN-KINASE ACTIVATION; NF-KAPPA-B; ENDOTHELIAL-CELLS; EXPRESSION; TRIAL; TARGET; GROWTH;

D O I：

10.2337/db12-1223

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：36 / 38

页数：3

共 21 条

[1]

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models [J].

Chen, Ying ;

Hu, Yang ;

Lin, Mingkai ;

Jenkins, Alicia J. ;

Keech, Anthony C. ;

Mott, Robert ;

Lyons, Timothy J. ;

Ma, Jian-xing .

DIABETES, 2013, 62 (01) :261-272

[2]

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. [J].

Chew, Emily Y. ;

Ambrosius, Walter T. ;

Davis, Matthew D. ;

Danis, Ronald P. ;

Gangaputra, Sapna ;

Greven, Craig M. ;

Hubbard, Larry ;

Esser, Barbara A. ;

Lovato, James F. ;

Perdue, Letitia H. ;

Goff, David C., Jr. ;

Cushman, William C. ;

Ginsberg, Henry N. ;

Elam, Marshall B. ;

Genuth, Saul ;

Gerstein, Hertzel C. ;

Schubart, Ulrich ;

Fine, Lawrence J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) :233-244

[3]

PPAR activators inhibit endothelial cell migration by targeting Akt [J].

Goetze, S ;

Eilers, F ;

Bungenstock, A ;

Kintscher, U ;

Stawowy, P ;

Blaschke, F ;

Graf, K ;

Law, RE ;

Fleck, E ;

Gräfe, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (05) :1431-1437

[4]

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials [J].

Hemmingsen, Bianca ;

Lund, Soren S. ;

Gluud, Christian ;

Vaag, Allan ;

Almdal, Thomas ;

Hemmingsen, Christina ;

Wetterslev, Jorn .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 343 :1136

[5]

PPARα: an emerging therapeutic target in diabetic microvascular damage [J].

Hiukka, Anne ;

Maranghi, Marianna ;

Matikainen, Niina ;

Taskinen, Marja-Riitta .

NATURE REVIEWS ENDOCRINOLOGY, 2010, 6 (08) :454-463

[6]

Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study [J].

Huang, W. P. ;

Yin, W. H. ;

Chen, J. W. ;

Jen, H. L. ;

Young, M. S. ;

Lin, S. J. .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (09) :775-783

[7]

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial [J].

Keech, A. C. ;

Mitchell, P. ;

Summonen, P. A. ;

O'Day, J. ;

Davis, T. M. E. ;

Moffitt, M. S. ;

Taskinen, M. R. ;

Simes, R. J. ;

Tse, D. ;

Williamson, E. ;

Merrifield, A. ;

Laatikainen, L. T. ;

d'Emden, M. C. ;

Crimet, D. C. ;

O'Connell, R. L. ;

Colman, P. G. .

LANCET, 2007, 370 (9600) :1687-1697

[8]

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway [J].

Kim, Jaetaek ;

Ahn, Ji-Hyun ;

Kim, Jeong-Hun ;

Yu, Young-Suk ;

Kim, Ho-Shik ;

Ha, Joohun ;

Shinn, Soon-Hyun ;

Oh, Yeon-Sahng .

EXPERIMENTAL EYE RESEARCH, 2007, 84 (05) :886-893

[9]

Kraja Aldi T., 2010, Endocrine Metabolic & Immune Disorders-Drug Targets, V10, P138

[10]

Effect of glycemic exposure on the risk of microvascular complications in the diabetes trial - Revisited [J].

Lachin, John M. ;

Genuth, Saul ;

Nathan, David M. ;

Zinman, Bernard ;

Rutledge, Brandy N. .

DIABETES, 2008, 57 (04) :995-1001

← 1 2 3 →